Hydralazine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydralazine hydrochloride and what is the scope of freedom to operate?
Hydralazine hydrochloride
is the generic ingredient in twenty-eight branded drugs marketed by Novartis, Abraxis Pharm, Am Regent, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Hikma, Kindos, Navinta Llc, Pharmobedient, Rising, Smith And Nephew, Solopak, Teva Parenteral, Teva, Actavis Elizabeth, Actavis Grp Ptc, Alkem Labs Ltd, Ascot, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Halsey, Heritage, Heritage Pharms Inc, Hetero Labs Ltd Iii, Impax Labs, Invagen Pharms, Ivax Sub Teva Pharms, Macleods Pharms Ltd, Mutual Pharm, Pliva, Purepac Pharm, Quantum Pharmics, Sciegen Pharms, Strides Pharma, Strides Pharma Intl, Superpharm, Tp Anda Holdings, Upsher Smith Labs, Usl Pharma, Vangard, Vitarine, Watson Labs, West Ward, Solvay, Ivax Pharms, Mylan, Sandoz, Sun Pharm Industries, Lederle, Azurity, I3 Pharms, and Ingenus Pharms Llc, and is included in one hundred and twenty-seven NDAs. Additional information is available in the individual branded drug profile pages.There are fifteen drug master file entries for hydralazine hydrochloride. Forty-four suppliers are listed for this compound.
Summary for hydralazine hydrochloride
| US Patents: | 0 |
| Tradenames: | 28 |
| Applicants: | 54 |
| NDAs: | 127 |
| Drug Master File Entries: | 15 |
| Finished Product Suppliers / Packagers: | 44 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 68 |
| Patent Applications: | 3,646 |
| Drug Prices: | Drug price trends for hydralazine hydrochloride |
| What excipients (inactive ingredients) are in hydralazine hydrochloride? | hydralazine hydrochloride excipients list |
| DailyMed Link: | hydralazine hydrochloride at DailyMed |
Recent Clinical Trials for hydralazine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tanta University | PHASE1 |
| University of Abuja | PHASE4 |
| University of Cambridge | PHASE4 |
Pharmacology for hydralazine hydrochloride
| Drug Class | Arteriolar Vasodilator |
| Physiological Effect | Arteriolar Vasodilation |
Medical Subject Heading (MeSH) Categories for hydralazine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for hydralazine hydrochloride
US Patents and Regulatory Information for hydralazine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rising | HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | INJECTABLE;INJECTION | 040730-001 | Apr 21, 2009 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Invagen Pharms | HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | TABLET;ORAL | 090255-002 | Dec 15, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Parenteral | HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | INJECTABLE;INJECTION | 040373-001 | Feb 23, 2000 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Strides Pharma Intl | HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | TABLET;ORAL | 088391-001 | Sep 27, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pliva | HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | TABLET;ORAL | 089097-001 | Dec 18, 1985 | AA | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch